Abstract: This invention relates to a micro-device for detecting volatile compounds comprising: an input (E) and an output (S); collection means (2) for taking a gas sample containing at least one compound to be detected; sampling means enabling a gas volume of 100 mL or less to be sampled, arranged after the collection means; injection means (3) of said gas sample; separation means (5) of the compound to be detected in the gas sample; compound detection means (6); and a gas circulation circuit (1) located downstream of the collection means and passing through the sampling means, injection means (3), separation means (5) and detection means (6); characterized in that the gas circulation circuit (1) has a volume of between 0.2 cm3 and 2.0 cm3.

Abstract: An injector, for injecting a fluidic sample into a flow path between a fluid drive and a sample separation unit, includes a sample accommodation volume, a sample drive, and a fluidic valve switchable to selectively couple the volume with the flow path or decouple the volume from the flow path. In an injection switching state, the fluid drive, the separation unit and the sample drive are coupled by the valve so that fluid driven by the sample drive and flowing from the volume to the separation unit and further fluid driven by the fluid drive and flowing from the fluid drive to the separation unit are combined at a fluidic connection upstream of the separation unit. A control unit controls a pressure of the fluid and/or the further fluid during injecting.

Abstract: A liquid chromatograph includes: a concentration column for capturing a target component; an analysis column for separating the target component from other components; first passage-switching units for switching between the state of forming a passage through which a sample-introduction mobile phase containing the liquid sample is fed to the concentration column, and the state of forming a passage through which an eluant for eluting the target component captured in the concentration column is fed to the concentration column; a storage unit for storing the eluant; and a second passage-switching unit for switching between the state of forming a passage through which an analysis mobile phase is fed to the analysis column and a passage through which the eluant from the concentration column is fed to the storage unit, and the state of forming a passage through which analysis mobile phase is fed to the analysis column via the storage unit.

Abstract: A sample management device which comprises a source flow path in which a fluidic sample can flow, a volume flow adjustment unit configured to adjust a volume flow of the fluidic sample to be branched off from the source flow path at a fluidic coupling point, and a fluidic valve fluidically coupled with the source flow path and with the volume flow adjustment unit, wherein the fluidic valve is switchable into a branch off state in which the fluidic coupling point is established within the source flow path to branch off an adjustable volume of the fluidic sample from the source flow path via the fluidic coupling point while a flow of the fluidic sample in the source flow path continues.

Abstract: An apparatus and method for generating olfactory information. The apparatus for generating olfactory information generates olfactory information that can be shared between a real world and at least one virtual world. The apparatus for generating olfactory information includes a sensor and a processor. The sensor recognizes a real-world odor, and acquires the original data of the result of the detection of the real-world odor. The processor acquires representative data including the evaluation of the quantitative numerical value of the real-world odor by analyzing the original data, and generates real-world olfactory information including both the original data and the representative data.

Abstract: A gas detection device includes a substrate having a main surface and a movable film structure located on, and including a portion thereof spaced from, the main surface of the substrate. The portion of the movable film structure located over and spaced from the substrate includes a first film formed of an insulating material, a patterned second film which deforms as a result of absorbing or adsorbing a predetermined gas, and a patterned third film comprising a resistive heater, at least a portion of the movable film structure spaced from the substrate being movable with respect to the substrate. From the perspective of a direction perpendicular to the main surface of the substrate, at least a portion of a pattern of the second film overlaps at least a portion of a pattern of the third film.

Abstract: Disclosed is an analysis system for analyzing water and wastewater, comprising an analysis device that includes a device housing which accommodates device components and which has an inlet on a housing surface, said inlet being designed as an injection port through which a substance to be analyzed can be introduced into a device component when the device housing is closed, and comprising a syringe that includes an injection needle outlet, the surface normal of which is congruent with the longitudinal axis; and/or the syringe includes an automatic ejection element for ejecting a predetermined amount of substance within a predetermined injection period.

Abstract: The mercury detecting paper provides a visual indication of the presence of mercury in an applied water sample. The mercury detecting paper is formed as a hydrophobic substrate having a reagent layer deposited thereon. The hydrophobic substrate is made from paper having a layer of hexamethyldisilazane (HMDS) deposited thereon, and the reagent layer is a layer of 6-hydroxy-3-(2-oxoindolin-3-ylideneamino)-2-thioxo-2H-1,3-thiazin-4(3H)-one (HOTT). In use, a water sample is applied to the reagent layer and a visual color change of the reagent layer upon contact with the water sample indicates a presence of mercury in the water sample. Specifically, HOTT turns a brick red color upon contact with Hg2+ ions.

Abstract: An exemplary embodiment provides a method of determining formation energy of a multi-element crystal, including: generating information related to a candidate structure of the multi-element crystal and information related to a metal pair included in the multi-element crystal, based on information related to a composition of the multi-element crystal; and determining the formation energy based on the information related to the candidate structure and the information related to the metal pair.

Abstract: The invention generally relates to methods of analyzing crude oil. In certain embodiments, methods of the invention involve obtaining a crude oil sample, and subjecting the crude oil sample to mass spectrometry analysis. In certain embodiments, the method is performed without any sample pre-purification steps.

Abstract: A mobile calorimeter includes a container comprising one or more walls defining a cavity. The container is adapted to hold a concrete mixture within the cavity. The mobile calorimeter also includes one or more heat flow sensors adapted to detect a heat flow generated by the concrete mixture. The heat flow sensors may include a thermoelectric device, a Peltier plate, or a macro fiber composite (MFC) sensor. The one or more heat flow sensors may be attached to the one or more walls, or may be embedded within the one or more walls. Data relating to a heat flow is obtained by the heat flow sensors, and is used to generate a prediction of a characteristic or performance of the concrete mixture.

Abstract: An evaluation method of abrasive grains used in an ingot-cutting slurry includes: an evaluation solution preparation step in which abrasive grains including polishing grains and impurities are dissolved in a solvent to prepare an evaluation solution; a sedimentation step in which a container containing the evaluation solution is left still to settle the polishing grains; a measurement step in which a turbidity of supernatant of the evaluation solution is measured using the measurement device; and an estimation step in which an amount of the impurities is estimated based on the measurement result of the turbidity of the supernatant.

Abstract: A method of analyzing a population of cells is disclosed. In certain embodiments, the method includes i) obtaining an array of cells on a substrate, wherein the cells are labeled with one or more mass tags and are separated from one another, ii) measuring, using secondary ion mass spectrometry (SIMS), the abundance of the one or more mass tags at a plurality of locations occupied by the cells, thereby generating, for each individual cell measured, a set of data, and iii) outputting the set of data for each of the cells analyzed. Also provided herein are systems that find use in performing the subject method. In some embodiments, the system is an automated system for analyzing a population of cells using SIMS.

Abstract: A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.

Abstract: A micro-electromechanical platform and array system and methods for identifying microbial species with single molecule electrical conductance measurements are provided. The electromechanical platform has a two-tier actuation mechanism with a long stroke provided by a comb drive and a fine stroke provided by an in-plane flexural actuator. The platform is capable of making contact with a single-molecule, applying a bias, measuring the current, and performing a large number of measurements for statistical analysis. The system is capable of detecting any microbial species without requiring enzymatic amplification by detecting specific RNA sequences, for example. With oligonucleotide target molecules, the conductance is extremely sensitive to the sequence so even single-nucleotide polymorphisms can be identified. The system can also discern between subspecies using the same DNA probe.

Abstract: A medical device includes a housing that has a front face and a side face. The housing defines a window cavity on the front face and a button cavity in the side face. A display is disposed in the housing. The display is aligned in the housing for viewing through the window cavity. A window covers the display in the window cavity, and the display is at least partially visible through the window. The window extends along the front face to the button cavity in the side face. A button element is received in the button cavity. The button element and the window are separate components. The button element has opposing end edges that align with the end edges of the window where the button element and window meet to provide an impression that the window and the button element are integral with one another.

Abstract: The present disclosure provides devices and methods using Plasma coil r separating a fluid—e.g., plasma or serum—from whole blood. In some embodiments, the devices and methods use hydrophobic or superhydrophobic surfaces to encourage whole blood to contact a selective membrane that extracts the desired fluid component from the blood.

Abstract: Methods and systems for constructing a gene expression signature representative of a number of biological conditions, systems and methods for determining functional relationships between a skin-active agent and skin conditions of interest, and methods and systems for identifying skin-active agents with broad spectrum activity are provided.

Abstract: A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, DNA, RNA. Furthermore, the method is to determine modulation of bile salt export transport and/or formation activity not only by said test agents, but further their metabolites or biotransformed products formed in situ. The bile salt export transport and/or formation activity modulation includes but not limited to inhibition, induction, activation and/or regulation. The method can be practiced to identify test agents, which have potential to cause liver injury, drug-drug interactions, and/or can be used as therapeutic agents for the treatment of cholestasis, abnormality of bile salt metabolism, liver diseases and cholesterol abnormality.

Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.

Abstract: A specimen analyzing method of an embodiment includes: preparing a measurement specimen from a biological specimen containing blood cells by staining, with a nucleic acid staining fluorescent dye, nucleic acids contained in neutrophils not having released neutrophil extracellular traps; obtaining optical information including fluorescence information by irradiating the measurement specimen with light; and detecting, as neutrophil extracellular traps on the basis of the optical information, particles having lower fluorescence intensity than fluorescence intensity obtained from the neutrophils not having released neutrophil extracellular traps.

Abstract: Methods and sensors for the detection, identification, and quantification of one or more gas species, including volatile organic compounds, in a test sample are described. Methods employ gas sensors comprising a diffusion matrix present on the sensor surface. A gas analyte in a test sample diffuses through the matrix and is detected upon interaction of the analyte with the sensor. A response profile of a gas sensor to a gas analyte in the test sample is compared to a control gas sensor response profile determined in a similar manner for a known gas species. Comparisons of test sample and control sample sensor response profiles enable detection, identification, and quantification of a gas species analyte in a test sample.

Abstract: Embodiments disclosed herein provide methods for identifying cell-type-specific nucleosomal DNA modifications. The methods leverage nucleosomal DNA barcoding and pool-and-split multiplexing to provide high-throughout, quantitative profiling of nucleosomal DNA states.

Abstract: Provided is a high-accuracy analysis method utilizing an enzyme-lined immunoassay. The presence of an analyte 3 can be detected or the abundance of the analyte 3 can be analyzed by: bonding an antibody 5 that is capable of specifically bonding to the analyte 3 immobilized on a solid phase 1 and has an enzyme 7 bonded thereto; then decomposing an enzyme substrate 8, which can generate decomposition products capable of being detected easily with a mass spectrometry, with the enzyme 7 bonded to the antibody 5; and then analyzing the decomposition products 9 and 10 with a mass spectrometry.

Abstract: The invention provides arrays of compound for use in profiling samples. The arrays include compounds bind to components of the samples at relatively low affinities. The avidity of compounds binding to components of the samples can be increased by forming arrays such that multivalent components of the samples (e.g., antibodies or cells) can bind to more than one molecule of a compound at the same time. When a sample is applied to an array under such conditions, the compounds of the array bind to component(s) of the sample with significantly different avidities generating a profile characteristic of the sample.

Abstract: Disclosed is an analysis method including: moving a complex, by means of a magnet unit, in a flow path of a specimen cartridge which includes the flow path and a detection vessel, the complex containing a test substance formed on magnetic particles and a labeled substance binding to the test substance; taking an image of the magnetic particles in the specimen cartridge; and measuring a label of the labeled substance contained in the complex in the detection vessel.

Abstract: The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers.

Abstract: Methods, devices, kits and compositions for detecting the presence or absence of one or more helminthic coproantigens in a sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm, whipworm and/or hookworm in a fecal sample from a mammal and may also be able to distinguish between one or more helminth infections. Confirmation of the presence or absence of roundworm, whipworm and/or hookworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.

Abstract: The present invention describes the use of nucleic acid barcodes as specific labels for MHC multimers to determine the antigen responsiveness in biological samples. After cellular selection the barcode sequence will be revealed by sequencing. This technology allows for detection of multiple (potentially >1000) different antigen-specific cells in a single sample. The technology can be used for T-cell epitope mapping, immune-recognition discovery, diagnostics tests and measuring immune reactivity after vaccination or immune-related therapies.

Abstract: The invention relates to murine monoclonal antibodies corresponding to monoclonal antibodies secreted by cell lines of hybridomas denominated 3G8/C11 and 7G4/A12, and which react against the antigen M of hMPV. Said antibodies do not compete with each other for the binding site for binding to the antigen, nor do they impede the simultaneous binding thereof to the antigen. Said monoclonal antibodies can be used for tests for the detection, diagnosis and/or determination of infection by hMPV.

Abstract: The present inventors have surprisingly found that a deoxyhypusine synthase (DHPS) gene, which was previously reported to correlate with prostate cancer and cervical cancer, is highly responsive to arteriosclerosis or digestive system cancer, whereby the gene can be used as a desired marker for arteriosclerosis or digestive system cancer. The present invention has been accomplished on the basis of this finding. Specifically, the present invention provides a method for determining arteriosclerosis or digestive system cancer, which method includes detecting expression of a deoxyhypusine synthase gene in a test sample (preferably a blood sample), and determining arteriosclerosis or digestive system cancer of a test subject from which the test sample has been obtained, on the basis of an increase in the gene expression as an index.

Abstract: The present disclosure relates to a method of prognosing and predicting breast cancer recurrence in patients, More particularly, the present disclosure relates to a method of prognosing which stratifies early stage ER+/PR+ and Her2? breast cancer patients with invasive ductal/lobular carcinoma of the breast into low risk or high risk for breast cancer recurrence by employing an IHC based assay which assesses or measures expression of a combination of 5 biomarkers and by employing a histopathological analysis which assesses 3 clinical prognostic parameters. The present disclosure also relates to a combination of 5 biological markers and 3 clinical prognostics markers employed in the method for prognosis of breast cancer, a kit/test comprising the antibodies against said markers for said prognosis and an IHC based assay system comprising said markers.

Abstract: A method for detecting and/or measuring circulating TXA2 in a subject having or at risk of having colorectal cancer. Generally, the method includes obtaining a biological sample from the subject, measuring circulating TXA2 in the biological sample, and identifying the subject as having colorectal cancer if the circulating TXA2 in the biological sample is greater than a predetermined level. The method may be used as a diagnostic test and/or may be performed repeatedly to monitor the status of colorectal cancer in a subject over time.

Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to CD38, are capable of killing CD3830 cells by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and/or complement-dependent cytotoxicity (CDC). Said antibodies and fragments thereof may be used in the treatment of tumors that express CD38 protein, such as multiple myeloma, chronic lymphocytic leukemia, chronic rnyelogenous leukemia, acute myelogenous leukemia, or acute lymphocytic leukemia, or the treatment of autoimmune and inflammatory diseases such as systemic lupus, rheumatoid arthritis, multiple sclerosis, erythematosus, and asthma.

Abstract: A method of diagnosing a potentially lethal prostate cancer in a patient comprising measuring one of a level of SAM Pointed Domain Containing ETS Transcription Factor (SPDEF) expression in the patient, a level of TWIST1 protein in the patient, and a level of matrix metalloproteinase 9 (MMP-9) expression in the patient, and diagnosing the patient with potentially lethal prostate cancer if one of the level of SPDEF in the patient is lower than a normal level of SPDEF, the level of TWIST1 in the patient is higher than a normal level of TWIST1, and the level of MMP-9 in the patient is higher than a normal level of MMP-9.

Abstract: The present invention is based on the identification of novel biomarkers predictive of responsiveness to a combination of anti-immune checkpoint and anti-angiogenesis therapies.

Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.

Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.

Abstract: Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.

Abstract: This disclosure relates to methods of assaying and scoring PD-L1 expression in tumors. Tumor samples are labeled with an antibody or antibody fragment that specifically binds to human PD-L1 and binding is detected. Binding intensity is compared to background, and tumor cells having membrane staining above background are counted. The percentage of tumor cells containing membrane staining of PD-L1 is determined and the tumor is classified as “PD-L1 positive” if the percentage of tumor cells falls above a predefined level.

Abstract: A diagnostic method for inflammatory diseases, and the diagnostic kit used in the method. The diagnostic method includes the use of a novel tryptophan metabolite, 5-methoxytryptophan (5-MTP), as a diagnostic biomarker of inflammation. Specifically, a highly specific competitive ELISA is provided to measure 5-MTP level in human serum for gauging occurrence and severity of inflammatory diseases, including sepsis and systemic lupus.

Abstract: Embodiments disclosed herein are directed to recognition tunneling systems, methods and devices, and more particularly, to chemical reactions for selectively labeling proteins and peptides and placing protein and/or peptides into, or onto a nanopore formed in a solid support and threading such in and/or through the nanopore, with such nanopores, in some embodiments, including a molecular motor to pull or otherwise force the protein/peptide through the nanopore.

Abstract: Peptide and/or protein quantitation methods, kits, and compositions, particularly useful for mass spectrometry, are provided herein based on a bathocuproine-based composition complex such as bathocuproinedisulfonic acid disodium salt hydrate complex. The methods are one-step rapid absorbance methods using small sample volumes. They produce a robust signal with high signal to background ratio and accurately quantitate even complex peptide mixtures with low variability and high sensitivity.

Abstract: Herein is reported an anti-drug antibody immunoassay for the determination of the presence of an anti-drug antibody against an effector function suppressed human or humanized drug antibody in a sample comprising the incubation of a sample comprising mammalian blood serum with full length human Fcgamma receptor I or an Fc-region binding fragment thereof so that a complex between the anti-drug antibody against the effector function suppressed human or humanized drug antibody present in the sample and the human Fcgamma receptor I or the Fc-region binding fragment thereof forms, whereby the full length human Fcgamma receptor I or the Fc-region binding fragment thereof is conjugated to a detectable label, and the determination of the formed complex by the detectable label.

Abstract: The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in tissue collected from female subjects.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.

Abstract: Non-invasive method for diagnosing or prognosing Alzheimer's disease, frontotemporal dementia, or other dementia involving isolating astrocyte-derived exosomes (ADEs) and neuron-derived exosomes (NDEs) from a human biological sample (i.e., plasma, serum, urine or cerebrospinal fluid), analyzing cargo extracts of the ADEs and NDEs to detect at least one specified protein or microRNA biomarker, comparing the levels and activities of detected biomarker(s) to those in control samples to identify a statistically significant difference between the detected biomarker(s) and corresponding biomarker(s) in the control sample to determine presence of Alzheimer's disease, frontotemporal dementia, or other dementia; and testing effects of drugs on levels and activities of each biomarker, as well as effects of drugs administered to test subjects on levels and activities of each biomarker in ADEs and NDEs from subsequently obtained biological samples.

Abstract: The present invention relates to the diagnosis of acquired sensory neuronopathies (SNN), and to the treatment of these disorders.

Abstract: The application relates to markers for seizures and epilepsy. Polypeptide expression panels or arrays are provided, comprising one or more probes capable of binding specific polypeptides in blood plasma or blood serum of a mammalian subject. Also provided are methods for detecting seizure, methods for predicting seizure, use of sICAM-5 in the treatment of seizure, methods for assessing the effectiveness of a treatment of seizure, and diagnostic kits.

Abstract: Methods and kits are provided for collecting samples for assessment of circadian timing in a non-clinical environment. The methods include monitoring light exposure of a subject and placing a first biological sample in a first sample vial, wherein the first biological sample is obtained in the non-clinical environment in dim light comprising light less than about 50 lux and monitoring the use of the first sample vial with a monitoring device. The methods include placing a second biological sample from the subject in a second sample vial, the second biological sample being taking at a time interval after the first biological sample and monitoring the use of the second sample vial with the monitoring device. Kits include a photosensor, a plurality of sample vials free from labels, a label system for labeling the plurality of sample vials, and a monitoring device for monitoring use of the plurality of sample vials.